Short Interest in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Increases By 38.3%

DiaMedica Therapeutics Inc. (NASDAQ:DMAC - Get Free Report) was the recipient of a significant increase in short interest during the month of May. As of May 15th, there was short interest totalling 856,900 shares, an increase of 38.3% from the April 30th total of 619,700 shares. Currently, 2.2% of the company's shares are sold short. Based on an average daily trading volume, of 93,700 shares, the short-interest ratio is presently 9.1 days.

DiaMedica Therapeutics Stock Performance

Shares of DMAC stock traded down $0.06 during trading on Thursday, hitting $4.14. The company had a trading volume of 40,487 shares, compared to its average volume of 83,330. The stock's 50-day moving average price is $3.90 and its 200 day moving average price is $4.98. DiaMedica Therapeutics has a one year low of $2.14 and a one year high of $6.82. The firm has a market capitalization of $177.58 million, a P/E ratio of -7.43 and a beta of 1.29.

DiaMedica Therapeutics (NASDAQ:DMAC - Get Free Report) last posted its quarterly earnings results on Tuesday, May 13th. The company reported ($0.18) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.18). During the same quarter last year, the company earned ($0.14) earnings per share. On average, research analysts anticipate that DiaMedica Therapeutics will post -0.59 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a "buy" rating and set a $10.00 price objective on shares of DiaMedica Therapeutics in a research report on Thursday, May 29th.

Hedge Funds Weigh In On DiaMedica Therapeutics

A number of hedge funds have recently added to or reduced their stakes in DMAC. Susquehanna International Group LLP grew its position in shares of DiaMedica Therapeutics by 269.5% during the 4th quarter. Susquehanna International Group LLP now owns 374,845 shares of the company's stock valued at $2,035,000 after acquiring an additional 273,395 shares during the period. Royal Bank of Canada raised its stake in DiaMedica Therapeutics by 46,879.1% in the first quarter. Royal Bank of Canada now owns 155,031 shares of the company's stock valued at $588,000 after purchasing an additional 154,701 shares in the last quarter. 683 Capital Management LLC purchased a new position in DiaMedica Therapeutics in the fourth quarter worth $413,000. Northern Trust Corp boosted its holdings in shares of DiaMedica Therapeutics by 49.8% in the 4th quarter. Northern Trust Corp now owns 180,192 shares of the company's stock worth $978,000 after purchasing an additional 59,902 shares in the last quarter. Finally, Jane Street Group LLC grew its position in DiaMedica Therapeutics by 138.5% during the first quarter. Jane Street Group LLC now owns 100,669 shares of the company's stock valued at $382,000 after acquiring an additional 58,457 shares during the last quarter. Institutional investors and hedge funds own 10.12% of the company's stock.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.